Navigation Links
Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Date:12/28/2007

de there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. currently co-promote VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patient
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... The "Operating Room Management Market ... Application (Perioperative, Preoperative, operating room Scheduling), by Component ... Global Forecast to 2019.” defines and segments the ... forecast of value by product, such as data ... the value and volumes of operating room management ...
(Date:11/15/2014)... 2014 The report “Laboratory ... End-User - Global Forecasts to 2019”, defines ... an analysis and forecast of value by ... Osmosis. Along with this, the value of ... regions are also discussed in the report. ...
(Date:11/15/2014)... 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the third quarter ended September 30, 2014. ... September 30, 2014 was $7.0 million, compared to $5.8 ... in net loss is mainly driven by higher research ... progress in both our Phase 3 systemic lupus erythematosus ...
(Date:11/12/2014)... , 12. November 2014 /PRNewswire/ ... RaySafe, ist weltweit führend in der ... biomedizinische Tests und Simulationen und diagnostische ... Nach dem erfolgreichen ... nun branchenweit in Hinsicht auf Produktqualität, ...
Breaking Biology Technology:Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 2Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 3Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 4Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 6Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 2Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 3Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 4Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 5
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 915.538 ... , , , , , , ... , Cell type , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.502 12/2001 ... , , , , , ... , Cell type , ...
... , Multiporator , , , , , , , ... Protocol No. 4308 915.034 11/1999 , , , , ... , Cell line , A 20, mouse ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
Cached Biology Technology:Bifidobacterium animalis 2Agrobacterium tumefaciens 2A 20 2
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Migration negation 2Migration negation 3
... complex of proteins in the bacterium E.coli that ... and other invaders has been discovered to have the shape ... Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab). This discovery holds ... think. In its never-ending battle to protect you from ...
... from the family goldfish might not be the result of a ... space turn mean, a study from Case Western Reserve University has ... 182.9 million of them. "The welfare of aquarium fishes ... captivity, they become a big deal," said Ronald Oldfield, an instructor ...
... sense of smell than researchers previously thought, contend scholars ... determine if they are related to a potential mate. ... the Chicago Zoological Society, which manages Brookfield Zoo, shows ... The study, published Wednesday, Sept. 21 in the article, ...
Cached Biology News:Close up look at a microbial vaccination program 2Close up look at a microbial vaccination program 3Close up look at a microbial vaccination program 4Aquarium fishes are more aggressive in reduced environments, a new study finds 2Aquarium fishes are more aggressive in reduced environments, a new study finds 3Smells may help birds find their homes, avoid inbreeding 2Smells may help birds find their homes, avoid inbreeding 3
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... it easy to supply microplates, deepwells, and ... operator convenience in mind, iLink incorporates multiple ... use. The iLink software is the key ... sub-assays, that can be copied and installed ...
... products bring you ease of use and rapid solutions to meet your laboratory's requirements for data ... ... ... CLARA® is the standard software for Staccato Systems ...
Biology Products: